Skip to content

Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal

Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03650153
Enrollment
165
Registered
2018-08-28
Start date
2020-01-01
Completion date
2022-12-31
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

This prospective study of comparing between Transrectal and transperineal prostate MRI targeted biopsy to provide evidence for clinicians to select the appropriate biopsy approach under different conditions.

Detailed description

This prospective study of comparing transperineal (TP) prostate MRI targeted biopsy with transrectal (TR) prostate MRI targeted biopsy was aimed to provide evidence for clinicians to select the appropriate biopsy approach under different conditions. TP (n = 75) and TR (n = 75) will be performed randomly for 150 patients who are suspicious of prostate cancer (PCa). The cancer detection rate (CDR), complication rate, visual analog scale (VAS) score, most painful procedure, number of repeated biopsy and additional anesthesia, and operating time (starting from lying down on the operating table to getting up) will be recorded.

Interventions

PROCEDURETrans-rectal MRI targeted Biopsy

Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.

PROCEDURETrans-perineal MRI targeted Biopsy

Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.

Sponsors

Princess Al-Johara Al-Ibrahim Cancer Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

* prostate-specific antigen \> 4ng/ml * Palpation is positive

Exclusion criteria

* older than 80y * prostate-specific antigen \> 100 ng/ml

Design outcomes

Primary

MeasureTime frameDescription
the rate of positive detections1 yearthe rate of positive detections (How many case are Prostate cancer positive)

Secondary

MeasureTime frameDescription
the incidence rate of each complication1 yearthe Incidence of complication rate is the number of complications divided by the number of patients and the number of patients with complications. Complications were separated into those with major or minor sequelae and the proportion of each type that were due to medical error (avoidable).

Other

MeasureTime frameDescription
Pain level assessed by visual analogue scale (VAS)1 yearThe pain VAS is a unidimensional measure of pain intensity used adult populations. The pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. Instructions, time period for reporting, and verbal descriptor anchors have varied widely in the literature depending on intended use of the scale. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Based on the distribution of pain VAS scores in postsurgical patients who described their postoperative pain intensity as none, mild, moderate, or severe, the following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75- 100 mm).

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026